What question did this study set out to answer?

SPECTRUM: Phase II study of tislelizumab plus pemetrexed in patients with relapsed or refractory (R/R) primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS)—The Korean Cancer Study Group LY22-07.

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and safety of tislelizumab plus pemetrexed in patients with relapsed or refractory primary DLBCL of the CNS.
Phase II, multicenter, open-label study in South Korea.
Patients received tislelizumab (200 mg) plus pemetrexed (500 mg/m2) intravenously every 3 weeks.
Primary endpoint was investigator-assessed objective response rate (ORR).
Among evaluable patients, ORR was 71.4% (20/28), with complete response rate of 50.0% (14/28).
Median progression-free survival was 6.8 months (95% CI, 2.1–27.6).
Median overall survival was 27.8 months (95% CI, 7.4–NR).

No takes yet. Share an insight, caveat, or question.

Randomized trial shows improved outcomes in patients with relapsed primary DLBCL of the CNS, suggesting effective options for this rare lymphoma.

Kim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows improved outcomes in patients with relapsed primary DLBCL of the CNS, suggesting effective options for this rare lymphoma.